Company Overview
Snapshot
Founded in June 2013 by Yossi Yamin and Martin Aebi, SpacePharma operates with 11–50 employees. The company has raised a total of $19.98M across four funding rounds. In March 2024, SpacePharma received a grant from the European Innovation Council.
Business overview
SpacePharma specializes in leveraging microgravity for research and development, providing end-to-end miniaturized lab systems equipped with sensors and readers. These systems, including their mGnify platform, are designed for remote control and use on various microgravity platforms, such as SpacePharma’s nanosatellites. The company supports clients through all stages of microgravity experiments, from planning and preparation to execution and analysis, serving the aerospace, defense, HLS, and life sciences sectors, particularly in pharmaceutical and medical biotechnology for drug discovery and development.
Strategic signal
In January 2026, SpacePharma R&D Israel Ltd was selected by the European Innovation Council's EIC Accelerator program to build SPACTORY, the first in-orbit monoclonal antibodies factory. This significant achievement, chosen from 968 proposals, validates SpacePharma's leadership in space-based biomanufacturing and signals a major step towards commercializing pharmaceutical production in microgravity, opening new avenues for drug development and manufacturing outside Earth's atmosphere.
Log in to access full profile ›Company Intelligence Q&A
- What is SpacePharma's core focus?
- SpacePharma focuses on utilizing microgravity for research and development, providing miniaturized, remotely controlled lab systems for experiments in space.
- When was SpacePharma founded and by whom?
- SpacePharma was founded in June 2013 by Yossi Yamin and Martin Aebi.
- What significant grant did SpacePharma receive recently?
- In March 2024, SpacePharma received a grant from the European Innovation Council.
- What is the SPACTORY project?
- In January 2026, SpacePharma R&D Israel Ltd was selected by the European Innovation Council's EIC Accelerator program to build SPACTORY, which will be the first in-orbit monoclonal antibodies factory outside the atmosphere.
- What collaboration is SpacePharma involved in for cancer research?
- In December 2024, BSGN, SpacePharma, and Roche collaborated on SPANCER, a project utilizing SpacePharma's microgravity labs to create consistent, high-quality 3D human tissues for developing better cancer diagnostics and treatments, supported by ESA's BSGN accelerator program.